The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
May 17th 2024
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Projected US Savings From Biosimilars, 2021-2025
Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Read More
Findings Are Reported From De-escalation Therapy in Early Breast Cancer
December 15th 2021Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.
Read More
Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer
December 7th 2021Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.
Read More
AMCP Nexus Survey: Two-Thirds of Payers Use Biosimilars to Manage Oncology Drug Costs
November 23rd 2021As the cost of oncology drugs increases, there has been a growing pressure to manage oncology drug spend, which some payers have done by establishing preferred therapies, including biosimilars.
Read More
FDA Deputy Director Discusses Initiatives to Advance Biosimilar Use
November 9th 2021An overview of activities at the FDA to promote the use of biosimilars was presented by Jacqueline Corrigan-Curay, JD, MD, principal deputy center director for the Center for Drug Evaluation and Research (CDER) at the FDA.
Read More
Dr Cate Lockhart Discusses Deciding Between Trastuzumab Biosimilars
October 28th 2021There are a number of trastuzumab biosimilars available, but so far there have not been any patient characteristics that have played a role in which ones are prescribed, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium.
Watch
Adalimumab Biosimilar Shows Equivalent Efficacy, Safety to Reference Humira for Psoriasis
October 20th 2021Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis.
Read More
Dr Kirollos Hanna Details How His Practice Chooses Which Biosimilars to Add to Its Formulary
October 16th 2021Kirollos Hanna, PharmD, manager of Oncology Pharmacy at the University of Minnesota Medical Center, explains the process behind how his practice chooses which biosimilars to stock and provide for patients.
Watch
Reference, Biosimilar Pegfilgrastim Can Be Safely Administered Same Day as Chemotherapy
October 12th 2021Investigators concluded that reference or biosimilar pegfilgrastim could be safely administered to patients with lymphoma on the same day they receive chemotherapy, which could reduce scheduling burden and risk of COVID-19 exposure.
Read More
Despite Awareness of Biosimilars, More Education Among Oncologists in Brazil Needed
October 6th 2021Brazilian oncologists showed a solid knowledge base about biosimilars and their safety; however, concerns over extrapolation and interchangeability requirements remained, suggesting that more education on these subjects is needed.
Read More
Dr Kashyap Patel: Misleading Reference Product Advertising and the Damage to Biosimlars' Reputation
October 2nd 2021Regulatory agencies have already begun calling companies out for misdirecting the public about the safety and efficacy of reference products in comparison to biosimilars, and it's important to continue to do so, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Watch
Bevacizumab Biosimilar Found to Have Safety, Efficacy Equivalent to Reference Avastin for NSCLC
October 1st 2021Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in patients with non–small cell lung cancer (NSCLC).
Read More
Dr Kashyap Patel: How COVID-19 Is Expected to Influence Usage of Biosimilar Pegfilgrastims
September 24th 2021The emergence of new COVID-19 variants and the lower-than-anticipated vaccination rates could lead to a greater use of pegfilgratim biosimilars in cancer settings, explained Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Watch
Dr Kashyap Patel: The Pros and Cons of Pegfilgrastim Biosimilars vs Neulasta Onpro
September 17th 2021Cost and lack of insurance are big drivers of why a physician may choose to prescribe a pegfilgrastim biosimilar over the convenient on-body device for the originator, said Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates.
Watch